In this edition, cancer and COVID-19 increase risk for thromboembolism, glofitamab shows curative potential in lymphoma, efgartigimod improves platelet counts, and more. Read the full coverage here: Biomarkers predict thromboembolism risk, mortality among people with cancer, COVID-19 Glofitamab shows 'curative potential' in relapsed/refractory diffuse large B-cell lymphoma Efgartigimod confers rapid improvement in platelet counts in immune thrombocytopenia Odronextamab 'potentially curative' in third-line setting for follicular lymphoma Dana-Farber professor receives William Dameshek Prize for multiple myeloma research References: Broome CM, et al. Abstract 3. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans. Hutchings M, et al. Abstract 441. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans. Khorana AA, et al. Abstract 136. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans. Kim TM, et al. Abstract 949. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans. Press Release

Ver todos los episodios